News | Cardiac Resynchronization Therapy Devices (CRT) | March 03, 2021

CRT May Benefit More Heart Failure Patients in New Analysis of REVERSE Trial

JACC Clinical Electrophysiology study findings highlight need to better classify heart failure outcomes


March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new analysis of the REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) clinical trial shows that patients whose heart failure stabilizes with CRT live longer, similar to patients whose condition improves with CRT. The manuscript was recently published in the Journal of American College of Cardiology: Clinical Electrophysiology.[1]

Heart failure impacts more than 6.5 million people in the U.S. As a progressive disease, it worsens over time, leading to a reduced quality of life, greater risk of complications and death. CRT is an established treatment for select patients with heart failure and has been demonstrated to improve survival and quality of life and reduce heart failure-related hospitalizations.

"It is commonly stated within the cardiology community that about a third of patients do not respond to CRT," said Michael R. Gold, M.D., Ph.D., Michael E. Assey Professor of Medicine at the Medical University of South Carolina, Charleston. "However, REVERSE shows that with mild heart failure, patient stability is a long-term benefit of CRT, similar to patient improvement. Our current classifications do not give us the full picture of how patients benefit from CRT. We need to redefine our current understanding of CRT response to include stability as a favorable outcome for this patient population."

The progression of heart failure can be measured in a number of ways. Clinical Composite Score (CCS) is used to categorize patient outcomes as improved, unchanged (stabilized), or worsened, which is determined using clinical measures, heart failure status and patient symptoms. Similarly, left ventricular end systolic volume index (LVESVi) assesses the amount of blood remaining in the left ventricle after contracting to determine the heart's effectiveness at pumping blood to meet the body's needs. Since survival decreases as LVESVi rises, this measure has been shown to be an important predictor of long-term outcomes in patients.

Using the CCS (406 patients), more than half (56%) of patients with mild heart failure improved at one year, 30% remained unchanged (or stabilized), and 14% worsened; five-year mortality for improved or stabilized patients was 10% compared to 21% for worsened patients, p=0.01. Using the LVESVi measure (353 patients), there was a 73% decrease in the risk of dying at five years for CRT patients who stabilized or improved, compared to those whose condition worsened (i.e., five-year mortality for improved or stabilized patients was 8% compared to 30% for worsened patients, p<0.01). Results of the trial showed a greater percentage of patients with mild heart failure benefited from CRT therapy, compared to current classifications.

"As we look for innovative solutions to reduce the burden of heart failure, the REVERSE analysis underscores that our CRT devices provide benefits for a larger number of patients than we previously understood," said Rob Kowal, M.D., Ph.D., chief medical officer of cardiac rhythm management, which is reported as part of the cardiac and vascular group at Medtronic. "REVERSE reinforces the strong clinical evidence supporting CRT, and the value of CRT as an option to slow the progression of this debilitating disease. Time and again, the landmark CRT trials have demonstrated a range of patient stabilization or improvement with the application of cardiac resynchronization therapy."

Optimized Implementation of Cardiac Resynchronization Therapy: A Call for Action for Referral and Optimization of Care, a recent position statement issued by the European Society of Cardiology (ESC) and its partners, similarly concluded that "a slowing of a progressive disease [such as heart failure] is a positive outcome," and "therefore 'stability' is seen as a positive outcome."[2]

The REVERSE trial was the first, large scale, global, randomized, double-blind study to evaluate the benefits of CRT for patients with mild HF – those designated as New York Heart Association Class I/II. The trial included 73 sites worldwide, including those in the U.S. Western Europe, and Canada.

The Medtronic portfolio of therapies, diagnostic tools and services for patients suffering from heart failure includes CRT devices, including MR-conditional CRT-defibrillators and CRT-pacemakers; mechanical circulatory support therapy for advanced heart failure patients; heart failure diagnostics; and meaningful expert analysis through Medtronic Care Management Services.

For more information: www.medtronic.com 

Find related content on CRT 

Find more EP news and video

References:

1. Michael R. Gold, John Rickard, J. Claude Daubert, et al. Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. J Am Coll Cardiol Clin Electrophysiol. Feb 24, 2021. Epublished DOI: 10.1016/j.jacep.2020.11.010.

2. Wilfried Mullens, Angelo Auricchio, Pieter Martens, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology. Eur J Heart Fail. 2020 Dec;22(12):2349-2369. doi: 10.1002/ejhf.2046.
 

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

February 26, 2018 — The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain ...

Home February 26, 2018
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

January 3, 2018 — Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) ...

Home January 03, 2018
Home
Subscribe Now